Severe, Symptomatic Hypocalcemia due to Denosumab Administration: Treatment and Clinical Course

We present 2 patients who developed severe, symptomatic hypocalcemia after administration of denosumab. These patients provide an opportunity to describe the clinical course and treatment, including the need to consider a continuous calcium infusion, of severe, symptomatic hypocalcemia caused by denosumab.Case Rep Nephrol Dial 2019;9:33 –41
Source: Case Reports in Nephrology and Dialysis - Category: Urology & Nephrology Source Type: research